A multiplex preclinical model for adenoid cystic carcinoma of the salivary gland identifies regorafenib as a potential therapeutic drug

Chen Chen, Sujata Choudhury, Darawalee Wangsa, Chamille J. Lescott, Devan J. Wilkins, Praathibha Sripadhan, Xuefeng Liu, Danny Wangsa, Thomas Ried, Christopher Moskaluk, Michael J. Wick, Eric Glasgow, Richard Schlegel, Seema Agarwal*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

35 Scopus citations

Abstract

Adenoid cystic carcinomas (ACC) are rare salivary gland cancers with a high incidence of metastases. In order to study this tumor type, a reliable model system exhibiting the molecular features of this tumor is critical, but none exists, thereby inhibiting in-vitro studies and the analysis of metastatic behavior. To address this deficiency, we have coupled an efficient method to establish tumor cell cultures, conditional reprogramming (CR), with a rapid, reproducible and robust in-vivo zebrafish model. We have established cell cultures from two individual ACC PDX tumors that maintain the characteristic MYB translocation. Additional mutations found in one ACC culture also seen in the PDX tumor. Finally, the CR/zebrafish model mirrors the PDX mouse model and identifies regorafenib as a potential therapeutic drug to treat this cancer type that mimic the drug sensitivity profile in PDX model, further confirming the unique advantages of multiplex system.

Original languageEnglish
Article number11410
JournalScientific Reports
Volume7
Issue number1
DOIs
StatePublished - 1 Dec 2017
Externally publishedYes

Fingerprint

Dive into the research topics of 'A multiplex preclinical model for adenoid cystic carcinoma of the salivary gland identifies regorafenib as a potential therapeutic drug'. Together they form a unique fingerprint.

Cite this